The regulatory variation is believed to play an important role in shaping phenotypic differences among individuals and thus is also very likely to influence disease susceptibility and progression. In this study, we propose to take advantage of the expression QTL mapping and co-expressed gene network analysis to identify and characterize candidate genes and genetic variants that are responsible for aggressive phenotype of prostate cancer. Our hypothesis is that most genetic variants responsible for an aggressive phenotype of prostate cancer have regulatory effect on candidate gene expression and complete understanding of regulatory SNPs can only be achieved by examining primary tissue (here, prostate). To test this hypothesis, we will use a case-case study design and apply an innovative yet feasible approach by integrating DNA sequence variation and gene expression with clinical trait information. The four Specific Aims are: 1. Identify novel aggressiveness-related candidate SNPs by utilizing an expression genetics-based eQTL mapping approach;2, Identify novel aggressiveness-related candidate SNPs by utilizing an integrative systems genetics-based network analysis approach;3. For the novel candidate SNPs identified in Aims 1 and 2, perform additional association-based studies to confirm their association with an aggressiveness-related phenotype for prostate cancer;and 4. Identify candidate causal-SNPs by fine mapping, recognizing that the candidate eSNPs identified in Aim 3 will most likely be in linkage disequilibrium with the causal-SNPs. Understanding genetic mechanisms underlying the aggressive phenotype will have significant impact on prevention strategies, prognosis and potentially targeted therapy.
Prostate cancer can be relatively harmless or extremely aggressive. The goal of this study is to identify and characterize genetic causes of the aggressive (clinically more significant) form of prostate cancer. An understanding the genetic mechanism underlying the aggressive disease will have a significant impact on prevention strategies, prognosis and potentially targeted therapy.
|Du, Meijun; Wang, Liang (2016) 3C-digital PCR for quantification of chromatin interactions. BMC Mol Biol 17:23|
|Wang, Yuan; Lieberman, Rachel; Pan, Jing et al. (2016) miR-375 induces docetaxel resistance in prostate cancer by targeting SEC23A and YAP1. Mol Cancer 15:70|
|Xia, Yun; Huang, Chiang-Ching; Dittmar, Rachel et al. (2016) Copy number variations in urine cell free DNA as biomarkers in advanced prostate cancer. Oncotarget 7:35818-35831|
|Du, Meijun; Tillmans, Lori; Gao, Jianzhong et al. (2016) Chromatin interactions and candidate genes at ten prostate cancer risk loci. Sci Rep 6:23202|
|Yuan, Tiezheng; Huang, Xiaoyi; Woodcock, Mark et al. (2016) Plasma extracellular RNA profiles in healthy and cancer patients. Sci Rep 6:19413|
|Huang, Xiaoyi; Yuan, Tiezheng; Liang, Meihua et al. (2015) Exosomal miR-1290 and miR-375 as prognostic markers in castration-resistant prostate cancer. Eur Urol 67:33-41|
|Larson, Nicholas B; McDonnell, Shannon; French, Amy J et al. (2015) Comprehensively evaluating cis-regulatory variation in the human prostate transcriptome by using gene-level allele-specific expression. Am J Hum Genet 96:869-82|
|Du, Meijun; Yuan, Tiezheng; Schilter, Kala F et al. (2015) Prostate cancer risk locus at 8q24 as a regulatory hub by physical interactions with multiple genomic loci across the genome. Hum Mol Genet 24:154-66|
|Hoffmann, Thomas J; Van Den Eeden, Stephen K; Sakoda, Lori C et al. (2015) A large multiethnic genome-wide association study of prostate cancer identifies novel risk variants and substantial ethnic differences. Cancer Discov 5:878-91|
|Xia, Shu; Kohli, Manish; Du, Meijun et al. (2015) Plasma genetic and genomic abnormalities predict treatment response and clinical outcome in advanced prostate cancer. Oncotarget 6:16411-21|
Showing the most recent 10 out of 13 publications